Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
April-2025 Volume 29 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
April-2025 Volume 29 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis

  • Authors:
    • Zhufeng Tong
    • Zhen Wang
    • Jinghan Jiang
    • Wenqi Fu
    • Siying Hu
  • View Affiliations / Copyright

    Affiliations: Department of General Practice, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China
    Copyright: © Tong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 207
    |
    Published online on: March 4, 2025
       https://doi.org/10.3892/ol.2025.14954
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The objective of the present study was to elucidate the mechanism by which glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer. Initially, A549 cells were treated with different concentrations of glycyrrhizin (0.25‑8 mM) or cisplatin (10‑160 µM) for 48 h to investigate the effect of glycyrrhizin combined with cisplatin on A549 cells in vitro. Subsequently, A549 cells were divided into control (untreated), CP (20 µM cisplatin), GL (2 mM glycyrrhizin) and CP + GL (20 µM cisplatin + 2 mM glycyrrhizin) groups to elucidate the underlying mechanism of glycyrrhizin. After 48 h incubation, the viability and colony‑forming ability of the cells were assessed using MTT and colony formation assays. Apoptosis levels and cell cycle progression were analyzed using flow cytometry and western blotting was used to evaluate apoptosis‑ and cell cycle‑related proteins. Additionally, comet assays and western blotting were used to evaluate DNA damage and relevant proteins. The results demonstrated both glycyrrhizin and cisplatin individually reduced A549 cell viability in a concentration‑dependent manner. Cisplatin demonstrated a lower half‑maximal inhibitory concentration (IC50) at higher glycyrrhizin concentrations, with an IC50 value of ~35 µM with 2 mM glycyrrhizin. Furthermore, the combined treatment of glycyrrhizin and cisplatin synergistically reduced cell colony‑forming ability, induced apoptosis and arrested the cell cycle at the G2 phase, showing greater efficacy when compared with either treatment individually. In addition, western blotting analysis demonstrated that, in comparison with treatment with cisplatin or glycyrrhizin alone, the combined treatment markedly increased the protein expression levels of B‑cell lymphoma 2‑associated X protein, cleaved‑caspase‑3/caspase‑3, γH2AX, phosphorylated‑checkpoint kinase 1 and phosphorylated‑p53/p53, while notably reducing the protein levels of B‑cell lymphoma 2, cyclin D1, cyclin‑dependent kinase 2 and cyclin‑dependent kinase 4. The findings of the present study indicate that glycyrrhizin enhances the antitumor efficacy of cisplatin in non‑small cell lung cancer cells by modulating DNA damage and apoptosis.
View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

View References

1 

Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI

2 

Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI

3 

Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W and Xia Y: Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 44:23–46. 2024. View Article : Google Scholar : PubMed/NCBI

4 

Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G and Reck M: Non-small-cell lung cancer. Nat Rev Dis Primers. 10:712024. View Article : Google Scholar : PubMed/NCBI

6 

Xu J and Gewirtz DA: Is autophagy always a barrier to cisplatin therapy? Biomolecules. 12:4632022. View Article : Google Scholar : PubMed/NCBI

7 

Dasari S, Njiki S, Mbemi A, Yedjou CG and Tchounwou PB: Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 23:15322022. View Article : Google Scholar : PubMed/NCBI

8 

Qi L, Luo Q, Zhang Y, Jia F, Zhao Y and Wang F: Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 32:1469–1486. 2019. View Article : Google Scholar : PubMed/NCBI

9 

Sun C, Gao W, Liu J, Cheng H and Hao J: FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 21:2102020. View Article : Google Scholar : PubMed/NCBI

10 

Gui YR, Zhang Y, Wang XQ, Fan BJ, Li JL, Zhang LX, Fan F, Cao KD, Zhang XG and Hou W: Treatment of lung cancer with orally administered Chinese herbal medicine: An evidence map between 1970–2020. Chin J Integr Med. 28:930–938. 2022. View Article : Google Scholar : PubMed/NCBI

11 

Singh M, Sharma P, Singh PK, Singh TG and Saini B: Medicinal potential of heterocyclic compounds from diverse natural sources for the management of cancer. Mini Rev Med Chem. 20:942–957. 2020. View Article : Google Scholar : PubMed/NCBI

12 

Masraksa W, Tanasawet S, Hutamekalin P, Wongtawatchai T and Sukketsiri W: Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway. Nutr Res Pract. 14:127–133. 2020. View Article : Google Scholar : PubMed/NCBI

13 

Kalaiarasi A, Anusha C, Sankar R, Rajasekaran S, John Marshal J, Muthusamy K and Ravikumar V: Plant isoquinoline alkaloid berberine exhibits chromatin remodeling by modulation of histone deacetylase to induce growth arrest and apoptosis in the A549 cell line. J Agric Food Chem. 64:9542–9550. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Deng QD, Lei XP, Zhong YH, Chen MS, Ke YY, Li Z, Chen J, Huang LJ, Zhang Y, Liang L, et al: Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Acta Pharmacol Sin. 42:1486–1497. 2021. View Article : Google Scholar : PubMed/NCBI

15 

Wei Z, Chen J, Zuo F, Guo J, Sun X, Liu D and Liu C: Traditional Chinese medicine has great potential as candidate drugs for lung cancer: A review. J Ethnopharmacol. 300:1157482023. View Article : Google Scholar : PubMed/NCBI

16 

Zhang Y, Yan S, Li Y, Zhang J, Luo Y, Li P, Yang Y, Li Y, Huang Y and Wang E: Inhibin βA is an independent prognostic factor that promotes invasion via Hippo signaling in non-small cell lung cancer. Mol Med Rep. 24:7892021. View Article : Google Scholar : PubMed/NCBI

17 

Zhang J, Li C, Zhang L, Heng Y, Xu T, Zhang Y, Chen X, Hoffman RM and Jia L: Andrographolide induces noxa-dependent apoptosis by transactivating ATF4 in human lung adenocarcinoma cells. Front Pharmacol. 12:6805892021. View Article : Google Scholar : PubMed/NCBI

18 

Wang Q, Jiao L, Wang S, Chen P, Bi L, Zhou D, Yao J, Li J, Wang L, Chen Z, et al: Adjuvant chemotherapy with Chinese herbal medicine formulas versus placebo in patients with lung adenocarcinoma after radical surgery: A multicenter, randomized, double-blind, placebo-controlled trial. Biol Proced Online. 22:52020. View Article : Google Scholar : PubMed/NCBI

19 

Chrzanowski J, Chrzanowska A and Graboń W: Glycyrrhizin: An old weapon against a novel coronavirus. Phytother Res. 35:629–636. 2021. View Article : Google Scholar : PubMed/NCBI

20 

Bravo V, Serrano M, Duque A, Ferragud J and Coronado PJ: Glycyrrhizinic acid as an antiviral and anticancer agent in the treatment of human papillomavirus. J Pers Med. 13:16392023. View Article : Google Scholar : PubMed/NCBI

21 

Han Y, Sheng W, Liu X, Liu H, Jia X, Li H, Wang C, Wang B, Hu T and Ma Y: Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response. Sci Rep. 14:249482024. View Article : Google Scholar : PubMed/NCBI

22 

Jain R, Hussein MA, Pierce S, Martens C, Shahagadkar P and Munirathinam G: Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights. Pharmacol Res. 178:1061382022. View Article : Google Scholar : PubMed/NCBI

23 

Zhang Y, Sheng Z, Xiao J, Li Y, Huang J, Jia J, Zeng X and Li L: Advances in the roles of glycyrrhizic acid in cancer therapy. Front Pharmacol. 14:12651722023. View Article : Google Scholar : PubMed/NCBI

24 

Wang H, Ge X, Qu H, Wang N, Zhou J, Xu W, Xie J, Zhou Y, Shi L, Qin Z, et al: Glycyrrhizic acid inhibits proliferation of gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Manag Res. 12:2853–2861. 2020. View Article : Google Scholar : PubMed/NCBI

25 

Huang RY, Chu YL, Jiang ZB, Chen XM, Zhang X and Zeng X: Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase. Cell Physiol Biochem. 33:375–388. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Deng QP, Wang MJ, Zeng X, Chen GG and Huang RY: Effects of glycyrrhizin in a mouse model of lung adenocarcinoma. Cell Physiol Biochem. 41:1383–1392. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Huan C, Xu Y, Zhang W, Guo T, Pan H and Gao S: Research progress on the antiviral activity of glycyrrhizin and its derivatives in liquorice. Front Pharmacol. 12:6806742021. View Article : Google Scholar : PubMed/NCBI

28 

Wakamatsu T, Nakahashi Y, Hachimine D, Seki T and Okazaki K: The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 31:1465–1472. 2007.PubMed/NCBI

29 

Tan JY, Zhao F, Deng SX, Zhu HC, Gong Y and Wang W: Glycyrrhizin affects monocyte migration and apoptosis by blocking HMGB1 signaling. Mol Med Rep. 17:5970–5975. 2018.PubMed/NCBI

30 

Ahmad A, Tiwari RK, Saeed M, Ahmad I and Ansari IA: Glycyrrhizin mediates downregulation of notch pathway resulting in initiation of apoptosis and disruption in the cell cycle progression in cervical cancer cells. Nutr Cancer. 74:622–639. 2022. View Article : Google Scholar : PubMed/NCBI

31 

Thirugnanam S, Xu L, Ramaswamy K and Gnanasekar M: Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep. 20:1387–1392. 2008.PubMed/NCBI

32 

Sun Y, Liu Y, Ma X and Hu H: The influence of cell cycle regulation on chemotherapy. Int J Mol Sci. 22:69232021. View Article : Google Scholar : PubMed/NCBI

33 

Carneiro BA and El-Deiry WS: Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020. View Article : Google Scholar : PubMed/NCBI

34 

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar

35 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021. View Article : Google Scholar : PubMed/NCBI

36 

Yan H, Jiang M, Yang F, Tang X, Lin M, Zhou C, Tan Y and Liu D: Ajuforrestin A, an abietane diterpenoid from Ajuga ovalifolia var. calanthe, induces A549 cell apoptosis by targeting SHP2. Molecules. 27:54692022. View Article : Google Scholar : PubMed/NCBI

37 

Roohbakhsh A, Iranshahy M and Iranshahi M: Glycyrrhetinic acid and its derivatives: Anti-cancer and cancer chemopreventive properties, mechanisms of action and structure-cytotoxic activity relationship. Curr Med Chem. 23:498–517. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Bi YY, Chen Q, Yang MY, Xing L and Jiang HL: Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 15:27592024. View Article : Google Scholar : PubMed/NCBI

39 

Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Mo Q, Zhao X, Fan Q, Deng F, et al: Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 68:1009382023. View Article : Google Scholar : PubMed/NCBI

40 

Su X, Wu L, Hu M, Dong W, Xu M and Zhang P: Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 95:670–678. 2017. View Article : Google Scholar : PubMed/NCBI

41 

Chen L, Yang J, Davey AK, Chen YX, Wang JP and Liu XQ: Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism. Xenobiotica. 39:955–963. 2009. View Article : Google Scholar : PubMed/NCBI

42 

Romani AMP: Cisplatin in cancer treatment. Biochem Pharmacol. 206:1153232022. View Article : Google Scholar : PubMed/NCBI

43 

Tsai JJ, Pan PJ, Hsu FT, Chung JG and Chiang IT: Glycyrrhizic acid modulates apoptosis through extrinsic/intrinsic pathways and inhibits protein kinase B- and extracellular signal-regulated kinase-mediated metastatic potential in hepatocellular carcinoma in vitro and in vivo. Am J Chin Med. 48:223–244. 2020. View Article : Google Scholar : PubMed/NCBI

44 

Cao R, Li Y, Hu X, Qiu Y, Li S, Xie Y, Xu C, Lu C, Chen G and Yang J: Glycyrrhizic acid improves tacrolimus-induced renal injury by regulating autophagy. FASEB J. 37:e227492023. View Article : Google Scholar : PubMed/NCBI

45 

Wang Y, Wang L, Luo R, Sun Y, Zou M, Wang T, Guo Q and Peng X: Glycyrrhizic acid against mycoplasma gallisepticum-induced inflammation and apoptosis through suppressing the MAPK pathway in chickens. J Agric Food Chem. 70:1996–2009. 2022. View Article : Google Scholar : PubMed/NCBI

46 

Liang B, Guo XL, Jin J, Ma YC and Feng ZQ: Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol. 21:5271–5280. 2015. View Article : Google Scholar : PubMed/NCBI

47 

Azzahra SNA, Hanif N and Hermawan A: MDM2 is a potential target gene of glycyrrhizic acid for circumventing breast cancer resistance to tamoxifen: Integrative bioinformatics analysis. Asian Pac J Cancer Prev. 23:2341–2350. 2022. View Article : Google Scholar : PubMed/NCBI

48 

Bentz GL, Lowrey AJ, Horne DC, Nguyen V, Satterfield AR, Ross TD, Harrod AE, Uchakina ON and McKallip RJ: Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. PLoS One. 14:e02175782019. View Article : Google Scholar : PubMed/NCBI

49 

Slovin S, Carissimo A, Panariello F, Grimaldi A, Bouché V, Gambardella G and Cacchiarelli D: Single-cell RNA sequencing analysis: A step-by-step overview. Methods Mol Biol. 2284:343–365. 2021. View Article : Google Scholar : PubMed/NCBI

50 

Wei C and Fu Q: Cell death mediated by nanotechnology via the cuproptosis pathway: A novel horizon for cancer therapy. View. 4:202300012023. View Article : Google Scholar

51 

Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S and Yu L: The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 11:3432020. View Article : Google Scholar : PubMed/NCBI

52 

Yang L, Liu YN, Gu Y and Guo Q: Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling. World J Gastrointest Oncol. 15:1739–1755. 2023. View Article : Google Scholar : PubMed/NCBI

53 

Zhang J, Zhou Q, Xie K, Cheng L, Peng S, Xie R, Liu L, Zhang Y, Dong W, Han J, et al: Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 40:2032021. View Article : Google Scholar : PubMed/NCBI

54 

Yang Y, Yang Z, Zhang R, Jia C, Mao R, Mahati S, Zhang Y, Wu G, Sun YN, Jia XY, et al: MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway. Biosci Rep. 41:BSR201920072021. View Article : Google Scholar : PubMed/NCBI

55 

Li H, Wen X, Ren Y, Fan Z, Zhang J, He G and Fu L: Targeting PI3K family with small-molecule inhibitors in cancer therapy: Current clinical status and future directions. Mol Cancer. 23:1642024. View Article : Google Scholar : PubMed/NCBI

56 

Omidi F, Shahbazi S, Reiisi S, Azhdari S and Karimzadeh MR: Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line. Toxicol In Vitro. 93:1056872023. View Article : Google Scholar : PubMed/NCBI

57 

Chueh FS, Hsiao YT, Chang SJ, Wu PP, Yang JS, Lin JJ, Chung JG and Lai TY: Glycyrrhizic acid induces apoptosis in WEHI-3 mouse leukemia cells through the caspase- and mitochondria-dependent pathways. Oncol Rep. 28:2069–2076. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Tong Z, Wang Z, Jiang J, Fu W and Hu S: Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis. Oncol Lett 29: 207, 2025.
APA
Tong, Z., Wang, Z., Jiang, J., Fu, W., & Hu, S. (2025). Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis. Oncology Letters, 29, 207. https://doi.org/10.3892/ol.2025.14954
MLA
Tong, Z., Wang, Z., Jiang, J., Fu, W., Hu, S."Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis". Oncology Letters 29.4 (2025): 207.
Chicago
Tong, Z., Wang, Z., Jiang, J., Fu, W., Hu, S."Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis". Oncology Letters 29, no. 4 (2025): 207. https://doi.org/10.3892/ol.2025.14954
Copy and paste a formatted citation
x
Spandidos Publications style
Tong Z, Wang Z, Jiang J, Fu W and Hu S: Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis. Oncol Lett 29: 207, 2025.
APA
Tong, Z., Wang, Z., Jiang, J., Fu, W., & Hu, S. (2025). Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis. Oncology Letters, 29, 207. https://doi.org/10.3892/ol.2025.14954
MLA
Tong, Z., Wang, Z., Jiang, J., Fu, W., Hu, S."Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis". Oncology Letters 29.4 (2025): 207.
Chicago
Tong, Z., Wang, Z., Jiang, J., Fu, W., Hu, S."Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis". Oncology Letters 29, no. 4 (2025): 207. https://doi.org/10.3892/ol.2025.14954
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team